Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Montelukast sodium plus rhTPO versus rhTPO for primary immune thrombocytopenia
ChiCTR2000039630Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jan 2021
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of montelukast and recombinant human thrombopoietin in immune thrombocytopenia (ITP) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoints: Platelet count, Hemoglobin and 1 more. Started Jan 2021; status: recruiting.
02
Drugs
montelukastrecombinant human thrombopoietin
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on ChiCTR2000039630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039630.